Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05688280 · ClinicalTrials.gov registry record · Phase 1
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
A Phase 1 study of Non-Small Cell Lung Cancer and Colon Cancer, sponsored by Immunophotonics.
- Active
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 16
- Study locations
NCT05688280: Active Phase 1 study of Non-Small Cell Lung Cancer and Colon Cancer, sponsored by Immunophotonics.
NCT05688280 is a Phase 1 study of Non-Small Cell Lung Cancer and Colon Cancer that is active but no longer recruiting, run by Immunophotonics. The registered enrollment target is 42 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 16 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05688280, a Phase 1 study of Non-Small Cell Lung Cancer and Colon Cancer, is active but no longer recruiting, sponsored by Immunophotonics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 16
- Study locations
Study Summary
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
Primary Outcome
The assessment of safety will be based on incidence of adverse events.
Conditions Studied
Interventions
- DRUG 1.0% IP-001 for Injection
Study Locations (16)
Other
- Institut Bergonie - Bordeaux
- Hospitalier Pitie-Salpetriere - Paris
- Hôpital Foch - Suresnes
- Institut Gustave Roussy - Villejuif
- Johann Wolfgang Goethe-Univresitat Frankfurt/Main - Frankfurt
- SLK-Kliniken Heilbronn GmbH - Heilbronn
- Munchen Klinik Bogenhausen - Munich
- IOSI Ospedale San Giovanni Bellinzona - Bellinzona
- Inselspital Universitatsspital, Bern - Bern
- Kantonsspital Graubunden - Chur
- Kantonsspital St. Gallen - Sankt Gallen
- University College London Hospitals - London
- Churchill Hospital - Oxford
Florida
- Miami Cardiac & Vascular Institute - Coral Gables
Kentucky
- University of Louisville Physicians, PSC - Louisville
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-11-29 |
| Est. Completion | 2025-02 |
| Phase | Phase 1 |
What the registry record for NCT05688280 still lists
NCT05688280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which 1.0% IP-001 for Injection is the first listed.
NCT05688280 lists 16 locations in 4 states (Other, Florida, Kentucky).
Frequently Asked Questions
What is clinical trial NCT05688280 about?
NCT05688280 is a clinical study titled "Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS". The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
What is the current status of trial NCT05688280?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-11-29. Estimated completion is 2025-02.
What conditions does trial NCT05688280 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colon Cancer, Soft Tissue Sarcoma, Metastatic Solid Tumor.
What interventions are being tested in trial NCT05688280?
The interventions under investigation include: 1.0% IP-001 for Injection (DRUG).
Who is sponsoring clinical trial NCT05688280?
This trial is sponsored by Immunophotonics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05688280 being conducted?
This trial has 16 study locations across Florida, Kentucky, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05688280's enrollment target sits among peer trials
42 352nd of 454 higher than 100 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI